Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Nivolumab/Ipilimumab Combination Receives FDA Approval in First-Line Treatment of Metastatic NSCLC

By: Jocelyn Solis-Moreira, MS
Posted: Tuesday, May 19, 2020

On May 15, the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor nivolumab (Opdivo) plus the monoclonal-antibody ipilimumab (Yervoy) as first-line treatment for metastatic non–small cell lung cancer (NSCLC). Patients are eligible if their tumors show 1% or greater expression of PD-L1, with no EGFR or ALK genomic tumor aberrations. The FDA also approved PD-L1 IHC 28-8 pharmDx as a companion diagnostic tool to select patients with NSCLC for this combination treatment.

The recommended doses in metastatic NSCLC are 3 mg/kg of nivolumab every 2 weeks and 1 mg/kg of ipilimumab every 6 weeks until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression.

The FDA approval is based on data from the open-label, multipart CheckMate 227 trial in patients with either metastatic or recurrent NSCLC who had no prior therapy. Of the 793 patients with a 1% or greater tumor expression of PD-L1, 336 were randomly assigned to receive nivolumab plus ipilimumab and 397, platinum-doublet chemotherapy.

The median overall survival was longer in patients who received nivolumab plus ipilimumab than in those who received platinum-doublet chemotherapy (17.1 vs. 14.9 months, respectively; hazard ratio [HR] = 0.79; 95% confidence interval [CI] = 0.67–0.94; P = .0066). The median progression-free survival was met with nivolumab plus ipilimumab compared with the platinum-doublet chemotherapy (5.1 vs. 5.6 months, respectively; HR = 0.82; 95% CI = 0.69–0.97). In addition, the overall response rate was 36% (95% CI = 31%–41%) versus 30% (95% CI = 26%–35%), respectively. The median response duration was longer with nivolumab plus ipilimumab at 23.2 months than ith the platinum-doublet chemotherapy at 6.2 months.

Common adverse reactions in 20% or more of patients receiving the combination treatment included fatigue, rash, decreased appetite, musculoskeletal pain, diarrhea/colitis, dyspnea, cough, pruritus, nausea, and hepatitis.

For more prescribing information, visit accessdata.fda.gov/opdivo and accessdata.fda.gov/yervoy.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.